Public Meeting on Patient-Focused Drug Development for Vitiligo - 03/30/2020 - 03/30/2020 | FDA

Public Meeting on Patient-Focused Drug Development for Vitiligo - 03/30/2020 - 03/30/2020 | FDA





Patient Focused Drug Development Meeting on Vitiligo

On Monday, March 30, 2020, FDA is conducting a public meeting on Patient Focused Drug Development for Vitiligo to hear directly from those with vitiligo to inform drug development efforts in this area.

FDA is interested in learning patients’ perspectives on vitiligo, including the effects on their health and well-being that have the greatest impact on daily life, their experience using prescription medical treatments and other treatments or therapies for vitiligo, and challenges or barriers to accessing or using medical treatments for vitiligo.

If you have any questions, please feel free to email us at patientfocused@fda.hhs.gov.